Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Key PointsWegovy patients lost an average of 16% of their body weight against 2% for placebo users in clinical trials.Zepbound patients lost 20.9% body weight and up to 26% after 88 weeks compared to 9.5% for the placebo group, but dosages rose to 15 mg a week versus 2.4 mg for Wegovy.Both drugs are being researched for additional indications, including cardiovascular, MASH and neurological diseases.5 stocks we like better than Novo Nordisk A/SThe GLP-1 weight loss trend continues to flourish, and the ante ...